PMID- 28008243
OWN - NLM
STAT- MEDLINE
DCOM- 20170808
LR  - 20181113
IS  - 1178-2005 (Electronic)
IS  - 1176-9106 (Print)
IS  - 1176-9106 (Linking)
VI  - 11
DP  - 2016
TI  - Efficacy of tiotropium-olodaterol fixed-dose combination in COPD.
PG  - 3163-3177
LID - 10.2147/COPD.S92840 [doi]
AB  - Tiotropium-olodaterol, formulated in the Respimat soft-mist inhaler, is an 
      inhaled fixed-dose combination (FDC) of a long-acting muscarinic antagonist 
      (LAMA) and a long-acting beta(2)-agonist (LABA), commercialized under the name of 
      Spiolto or Stiolto. The efficacy of tiotropium-olodaterol 5-5 mug once daily in 
      adult patients with COPD was documented in eleven large, multicenter trials of up 
      to 52 weeks duration. Tiotropium-olodaterol 5-5 mug not only improved spirometric 
      values to a significantly greater extent than placebo but also resulted in 
      statistically significant beneficial effects on dyspnea, markers of 
      hyperinflation, use of rescue medication, health-related quality of life, and 
      exercise endurance. Improvements exceeded the minimal clinically important 
      difference (MCID) for forced expiratory volume in 1 second (FEV(1)), dyspnea, and 
      quality of life. Differences between tiotropium-olodaterol 5-5 mug and the 
      respective monocomponents were statistically significant for FEV(1), dyspnea, 
      markers of hyperinflation, use of rescue medication, and health-related quality 
      of life, but did not reach the MCID. However, dual bronchodilatation 
      significantly increased the number of patients who exceeded the MCID for dyspnea 
      and quality of life. Moreover, tiotropium-olodaterol 5-5 mug was significantly 
      more effective than salmeterol-fluticasone (FDC) twice daily at improving 
      pulmonary function. Differences between tiotropium-olodaterol and other LAMA/LABA 
      FDCs were not observed for FEV(1) or other efficacy markers. Therefore, 
      tiotropium-olodaterol is a valuable option in the treatment of COPD patients who 
      remain symptomatic under monotherapy.
FAU - Derom, Eric
AU  - Derom E
AD  - Department of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium.
FAU - Brusselle, Guy G
AU  - Brusselle GG
AD  - Department of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium.
FAU - Joos, Guy F
AU  - Joos GF
AD  - Department of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20161213
PL  - New Zealand
TA  - Int J Chron Obstruct Pulmon Dis
JT  - International journal of chronic obstructive pulmonary disease
JID - 101273481
RN  - 0 (Adrenergic beta-2 Receptor Agonists)
RN  - 0 (Benzoxazines)
RN  - 0 (Bronchodilator Agents)
RN  - 0 (Drug Combinations)
RN  - 0 (Muscarinic Antagonists)
RN  - 0 (tiotropium-olodaterol)
RN  - XX112XZP0J (Tiotropium Bromide)
SB  - IM
MH  - Administration, Inhalation
MH  - Adrenergic beta-2 Receptor Agonists/*administration & dosage/adverse effects
MH  - Benzoxazines/*administration & dosage/adverse effects
MH  - Bronchodilator Agents/*administration & dosage/adverse effects
MH  - Drug Combinations
MH  - Exercise Tolerance/drug effects
MH  - Forced Expiratory Volume
MH  - Humans
MH  - Lung/*drug effects/physiopathology
MH  - Muscarinic Antagonists/*administration & dosage/adverse effects
MH  - Pulmonary Disease, Chronic Obstructive/diagnosis/*drug therapy/physiopathology
MH  - Quality of Life
MH  - Recovery of Function
MH  - Time Factors
MH  - Tiotropium Bromide/*administration & dosage/adverse effects
MH  - Treatment Outcome
PMC - PMC5167492
OTO - NOTNLM
OT  - COPD
OT  - LABA
OT  - LAMA
OT  - bronchodilatation
OT  - dyspnea
OT  - exacerbation
OT  - exercise tolerance
OT  - spirometry
COIS- The authors report no conflicts of interest in this work.
EDAT- 2016/12/23 06:00
MHDA- 2017/08/09 06:00
PMCR- 2016/12/13
CRDT- 2016/12/24 06:00
PHST- 2016/12/24 06:00 [entrez]
PHST- 2016/12/23 06:00 [pubmed]
PHST- 2017/08/09 06:00 [medline]
PHST- 2016/12/13 00:00 [pmc-release]
AID - copd-11-3163 [pii]
AID - 10.2147/COPD.S92840 [doi]
PST - epublish
SO  - Int J Chron Obstruct Pulmon Dis. 2016 Dec 13;11:3163-3177. doi: 
      10.2147/COPD.S92840. eCollection 2016.